Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
University of California, San Francisco
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02587650CT.gov Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · NTRK Fusion Positive Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capmatinib (this asset) | University of California, San Francisco | P2 | CCC · 48 |
| bay2757556 | Bayer | P2 | BB |
| Larotrectinib | Bayer | P1/2 | BB |
| Selitrectinib | Bayer | P1 | CCC |
| Regorafenib | University of California, San Francisco | P2 | CCC |
| Ceritinib | University of California, San Francisco | P2 | CCC |
| Entrectinib | University of California, San Francisco | P2 | CCC |
| cg001419 tablets | Cullgen (Shanghai),Inc | P1/2 | CCC |
| Selitrectinib Pediatric | Bayer | P1 | CC |
+5 more in the NTRK Fusion Positive Cancer cohort
Other indications for Capmatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | B · 59 |
| Neoplasm | — | P2/3 | CCC · 55 |
| Hepatocellular Carcinoma | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capmatinib in NTRK Fusion Positive Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capmatinib-ntrk-fusion-positive-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →